Lead Product(s): Semaglutide
Therapeutic Area: Neurology Product Name: Rybelsus
Highest Development Status: Preclinical Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 16, 2020
Novo Nordisk announced the decision to enter phase 3 development in Alzheimer’s disease with 14 mg oral semaglutide, a once-daily oral formulation of the long-acting GLP-1 analogue semaglutide.
Lead Product(s): Arimoclomol
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Michael J. Fox Foundation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 17, 2020
Orphazyme’s drug candidate arimoclomol has potential across a range of neurodegenerative diseases, including GCase-deficient Parkinson’s disease (PD).